News

Cosmo places Santarus shares
Enlarge image

BusinessItaly

Cosmo places Santarus shares

14.05.2013 - Cosmo Pharmaceuticals' subsidiary Cosmo Technologies Ltd, has placed 4,250,000 Santarus shares in a secondary public offering to investors in the US.

After having placed 4,250,000 of its 7,878,544 Santarus shares to US investors, the sole bookrunner Jefferies LLC, exercised an option to purchase additional 637,500 Santarus shares at the same price.

The specialist for gastro-intestinal and skin disorders did not sell any shares and will not receive any proceeds from the offering. The transaction is expected to close on May 15, subject to satisfaction of customary closing conditions. The shares were originally purchased at an average price of € 1.77. Per year end 2012 each share was worth € 8.32.  

Cosmo’s proprietary clinical development pipeline specifically addresses treatments for IBD, such as ulcerative colitis and Crohn’s disease, and colon infections. Additionally, the company is developing a diagnostic tool for the detection of colon cancer and a new drug for the topical treatment of Acne, Alopecia and Hirsutism. Cosmo’s first product on the market is Lialda®/Mezavant®/Mesavancol®, a treatment for mild to moderate ulcerative colitis that is licensed globally to Giuliani and Shire Limited. Cosmo’s second product is Uceris™/Cortiment™, a steroid with low side effects that is indicated for ulcerative colitis patients that do not get relief when treated with 5-ASA’s, and which is licensed globally to Santarus and Ferring.

Cosmo’s proprietary MMX® technology is at the core of the company’s product pipeline and was developed through its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (facilities in Lainate, Italy. The technology of the young company is designed to targeted delivery of active ingredients in the intestines.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/cosmo-places-santarus-shares.html

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX4.84 EUR34.82%
  • FORMYCON31.25 EUR11.61%
  • PAION2.76 EUR6.98%

FLOP

  • MEDIGENE12.41 EUR-3.42%
  • SANTHERA96.75 CHF-2.12%
  • MOLOGEN5.01 EUR-1.18%

TOP

  • WILEX4.84 EUR63.5%
  • FORMYCON31.25 EUR35.0%
  • CO.DON3.35 EUR29.8%

FLOP

  • CYTOS1.08 CHF-22.9%
  • BIOTEST78.40 EUR-18.9%
  • THERAMETRICS0.07 CHF-12.5%

TOP

  • SANTHERA96.75 CHF2368.1%
  • CYTOS1.08 CHF671.4%
  • WILEX4.84 EUR469.4%

FLOP

  • MOLOGEN5.01 EUR-55.5%
  • BIOFRONTERA2.40 EUR-26.8%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.04.2015